CD44 also has shown conflicting results in its prognostic value related to OS patients. In 2015, Gao et al. examined 114 human OS tumor specimens from primary, metastatic, and recurrent stages, and determined that CD44 was overexpressed in metastatic and recurrent OS as compared with primary tumors with higher expression of CD44 in patients with shorter survival and patients who exhibited unfavorable response to chemotherapy before surgical resection [9]. The gene discussed is CD44; the disease is neoplasm.